Equity Details
Price & Market Data
Price: $55.00
Daily Change: -$0.78 / 1.42%
Daily Range: $53.50 - $56.31
Market Cap: $5,316,605,440
Daily Volume: 778,125
Performance Metrics
1 Week: -4.70%
1 Month: -6.14%
3 Months: 29.02%
6 Months: 43.79%
1 Year: 53.42%
YTD: 22.71%
About Xenon Pharmaceuticals Inc. (XENE)
Comprehensive financial data on Xenon Pharmaceuticals Inc. (XENE). Trading at 55.00, it has a daily change of -$0.78 / 1.42%. Market cap: 5,316,605,440. Review its performance from the last week to the last year.
Company Details
Employees: 370
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.